We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Sensor Technology Detects Diabetes by Breath Analysis

By LabMedica International staff writers
Posted on 02 Jul 2013
A sensor technology could significantly simplify the diagnosis and monitoring of diabetes through breath analysis alone. More...


Physicians often recognize patients with diabetes through the condition's symptoms such as their characteristic breath of acetone, an odor that increases significantly with high glucose levels.

Chemists at the University of Pittsburgh (PA, USA) used a sol-gel approach, a method for using small molecules, often on a nanoscale level, to produce solid materials. The team combined titanium dioxide with carbon nanotubes, which acted as "skewers" to hold the particles together. These nanotubes were used because they are stronger than steel and smaller than any element of silicon-based electronics.

This method, which the scientists called "titanium dioxide on a stick," effectively combined the electrical properties of the tubes with the light-illuminating powers of the titanium dioxide. They then created the sensor device by using these materials as an electrical semiconductor, measuring its electrical resistance, which is the sensor's signal. They found the sensor could be activated with light to produce an electrical charge. This prompted them to expose the nanotubes in the sensor under ultraviolet light to measure acetone vapors, which they found were lower than previously reported sensitivities.

The authors concluded that the ultrahigh sensitivity to parts per million (ppm) level of acetone vapors, fast and reversible response, together with miniature size and room temperature operation makes this nanohybrid device a promising sensing platform that could find applications in the detection of breath acetone. The development of a micro-sized low-power electronic breath acetone-sensor device could further benefit personal healthcare by serving as a convenient and low-cost diagnostic tool for diabetes or a novel and high-throughput analytical method in the clinical studies of metabolic disorders.

Alexander Star, PhD, the lead author said, “Current monitoring devices are mostly based on blood glucose analysis, so the development of alternative devices that are noninvasive, inexpensive, and provide easy-to-use breath analysis could completely change the paradigm of self-monitoring diabetes. Our measurements have excellent detection capabilities. If such a sensor could be developed and commercialized, it could transform the way patients with diabetes monitor their glucose levels." The study was published on May 21, 2013, in the Journal of the American Chemical Society.

Related Links:
University of Pittsburgh



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.